Lara Davis, MD
Medical Oncology · Portland, ORNPI 1508992215
Payments from drug & device makers
Across 235 payments — averaging $9613.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$656K
- GSK$484K
- BTG International Inc.$402K
- Eisai Inc.$262K
- Epizyme, Inc.$246K
- Servier Bioinnovation$66K
- plus $142K from 9 others
Across 4 payments — averaging $1917.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 3 | $656,336 |
| GSK | 63 | $484,451 |
| BTG International Inc. | 5 | $402,392 |
| Eisai Inc. | 22 | $261,705 |
| Epizyme, Inc. | 39 | $246,044 |
| Servier Bioinnovation | 41 | $66,421 |
| Springworks Therapeutics, Inc. | 23 | $55,611 |
| Karyopharm Therapeutics Inc. | 12 | $40,282 |
| Daiichi Sankyo Inc. | 13 | $14,180 |
| Adaptimmune LLC | 3 | $14,050 |
| Boehringer Ingelheim | 1 | $7,950 |
| Eli Lilly | 1 | $4,170 |
| Regeneron | 2 | $3,624 |
| Aadi Bioscience, Inc. | 4 | $1,090 |
| Deciphera Pharmaceuticals Inc. | 3 | $885 |
How this compares
$2,259,191 in reported general payments places this provider in the 80th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Portland
- Matthew TaylorPortland$25.1M
- Rachel SanbornPortland$17.2M
- Christopher RyanPortland$10.3M
- Brendan CurtiPortland$8.6M
- Zahi MitriPortland$8.5M
- Julie GraffPortland$8.5M
- Shivaani KummarPortland$7.8M
- Rom LeidnerPortland$5.5M
- Charles LopezPortland$5.3M
- David PagePortland$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.